keyword
MENU ▼
Read by QxMD icon Read
search

Bevacizumab glioblastoma

keyword
https://www.readbyqxmd.com/read/28638456/temozolomide-and-bevacizumab-induction-before-chemoradiotherapy-in-patients-with-bulky-glioblastoma-and-or-with-severe-neurological-impairment
#1
Ilan Darmon, Mony Chenda Morisse, Alexandre Coutte, Marie Blonski, Emilie Le Rhun, Luc Taillandier, Diana Bello Roufai, Christine Desenclos, Stéphanie Trudel, Jean-Christophe Faivre, Nicolas Blanchard, Bruno Chauffert, Mathieu Boone
Background. New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy. Bevacizumab (BEV), an antiangiogenic anti-VEGF-R monoclonal antibody, has a rapid impact on tumor-related brain edema in recurrent GB. The present study reports the feasibility and efficacy of an induction treatment with TMZ and BEV to alleviate the initial neurological impairment and/or to reduce the tumor volume before a delayed chemoradiotherapy...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28634311/-bevacizumab-related-hyperintense-lesions-on-diffusion-weighted-imaging-at-different-locations-in-a-patient-with-malignant-glioma
#2
Shinya Oshiro, Naoki Wakuta, Shinichi Kawai, Koichi Miki, Yutaka Shigemori
We report the case of a 60-year-old man who first presented with transient difficulty of word recall. Subsequent MRI revealed an invasive brain tumor in the left frontal lobe. The patient underwent open biopsy, and diffuse astrocytoma(WHO grade II)was diagnosed. However, the malignant potential of this tumor was not particularly low because of a few enhancement on preoperative evaluation, and radiation therapy was initially performed. Four months after ending irradiation, temozolomide treatment was introduced for tumor regrowth...
June 2017: No Shinkei Geka. Neurological Surgery
https://www.readbyqxmd.com/read/28631191/effect-of-angiotensin-system-inhibitors-on-survival-in-newly-diagnosed-glioma-patients-and-recurrent-glioblastoma-patients-receiving-chemotherapy-and-or-bevacizumab
#3
Victor A Levin, James Chan, Meenal Datta, Jennie L Yee, Rakesh K Jain
Given prior studies that suggest the use of angiotensin system inhibitors (ASIs) is associated with prolonged overall survival (OS) in glioblastoma (GBM) patients, we evaluated the effect of ASIs in glioma patients receiving chemotherapy and/or bevacizumab (BEV). Using retrospective IRB-approved electronic chart review of newly diagnosed WHO grade 2-4 glioma patients from the Kaiser Permanente Tumor Registry of Northern California, we evaluated the impact of ASIs on OS by Cox proportional hazard model analysis for subgroups who received cytotoxic therapy, cytotoxic therapy with BEV, or BEV alone, as well as those with recurrent GBM (rGBM)...
June 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28627960/lack-of-functional-normalisation-of-tumour-vessels-following-anti-angiogenic-therapy-in-glioblastoma
#4
Nina Obad, Heidi Espedal, Radovan Jirik, Per Oystein Sakariassen, Cecilie Brekke Rygh, Morten Lund-Johansen, Torfinn Taxt, Simone P Niclou, Rolf Bjerkvig, Olivier Keunen
Neo-angiogenesis represents an important factor for the delivery of oxygen and nutrients to a growing tumour, and is considered to be one of the main pathodiagnostic features of glioblastomas (GBM). Anti-angiogenic therapy by vascular endothelial growth factor (VEGF) blocking agents has been shown to lead to morphological vascular normalisation resulting in a reduction of contrast enhancement as seen by magnetic resonance imaging (MRI). Yet the functional consequences of this normalisation and its potential for improved delivery of cytotoxic agents to the tumour are not known...
January 1, 2017: Journal of Cerebral Blood Flow and Metabolism
https://www.readbyqxmd.com/read/28616662/perifosine-enhances-bevacizumab-induced-apoptosis-and-therapeutic-efficacy-by-targeting-pi3k-akt-pathway-in-a-glioblastoma-heterotopic-model
#5
Sara Ramezani, Nasim Vousooghi, Fatemeh Ramezani Kapourchali, Mohammad Taghi Joghataei
Bevacizumab (BVZ) as an antiangiogenesis therapy leads to a transient therapeutic efficacy in high-grade glioma. However, the proapoptotic potential of BVZ has not been well elucidated, yet. There is also a tumor resistance to BVZ that is linked to post-treatment metalloproteinases and AKT activities. Herein, the association between therapeutic efficacy and putative proapoptotic activity of low-dose BVZ either alone or in combination with a specific inhibitor of AKT called perifosine (PRF), in a glioma model was investigated...
June 14, 2017: Apoptosis: An International Journal on Programmed Cell Death
https://www.readbyqxmd.com/read/28597184/epithelial-membrane-protein-2-emp2-promotes-angiogenesis-in-glioblastoma-multiforme
#6
Yu Qin, Masamichi Takahashi, Kristopher Sheets, Horacio Soto, Jessica Tsui, Panayiotis Pelargos, Joseph P Antonios, Noriyuki Kasahara, Isaac Yang, Robert M Prins, Jonathan Braun, Lynn K Gordon, Madhuri Wadehra
Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumor and is associated with an extremely poor clinical prognosis. One pathologic hallmark of GBM is excessive vascularization with abnormal blood vessels. Extensive investigation of anti-angiogenic therapy as a treatment for recurrent GBM has been performed. Bevacizumab, a monoclonal anti-vascular endothelial growth factor A (VEGF-A), suggests a progression-free survival benefit but no overall survival benefit. Developing novel anti-angiogenic therapies are urgently needed in controlling GBM growth...
June 9, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28594901/detection-of-human-cytomegalovirus-in-glioblastoma-among-taiwanese-subjects
#7
Ching-Fen Yang, Hsiang-Ling Ho, Shih-Chieh Lin, Chih-Yi Hsu, Donald Ming-Tak Ho
The relationship between human cytomegalovirus (HCMV) and glioblastoma (GBM) has been debated for more than a decade. We investigated the presence of HCMV genes, RNA and protein in GBMs and their relationships with tumor progression. Results of quantitative PCR for HCMV UL73, nested PCR for HCMV UL144, in situ hybridization (ISH) for RNA transcript, and immunohistochemistry (IHC) for protein expression and their relationship to the prognosis of 116 patients with GBM were evaluated. Nine (7.8%) cases revealed a low concentration of HCMV UL73, and only 2 of the 9 (1...
2017: PloS One
https://www.readbyqxmd.com/read/28562358/a-phase-2-study-of-the-first-imipridone-onc201-a-selective-drd2-antagonist-for-oncology-administered-every-three-weeks-in-recurrent-glioblastoma
#8
Isabel Arrillaga-Romany, Andrew S Chi, Joshua E Allen, Wolfgang Oster, Patrick Y Wen, Tracy T Batchelor
ONC201 is an oral, small molecule selective antagonist of the G protein-coupled receptor DRD2 that causes p53-independent apoptosis in tumor cells via integrated stress response activation and Akt/ERK inactivation. We performed a Phase II study that enrolled 17 patients with recurrent, bevacizumab-naïve, IDH1/2 WT glioblastoma who received 625mg ONC201 every three weeks. Median OS was 41.6 weeks with OS6 of 71% and OS9 of 53%. Seven of 17 patients are alive. PFS6 was 11.8% with two patients remaining on study who continue to receive ONC201 for >12 months...
May 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/28555422/ischemic-stroke-and-intracranial-hemorrhage-in-patients-with-recurrent-glioblastoma-multiforme-treated-with-bevacizumab
#9
Timo A Auer, Mirjam Renovanz, Federico Marini, Marc A Brockmann, Yasemin Tanyildizi
Bevacizumab (BVZ), a monoclonal antibody directed against vascular endothelial growth factor (VEGF), has been suspected to increase the incidence of ischemic stroke (IS) and intracranial hemorrhage (ICH) in GBM patients. Intracranial vascular events, such as IS and ICH, were retrospectively analyzed in 364 MRI scans of 82 patients with recurrent GBM (1st/2nd/3rd relapse). Out of these 82 patients, 40 were treated with BVZ (178 scans) in addition to basic treatment, whereas 42 patients matching for age and gender received basic treatment (186 scans)...
May 29, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28536525/immune-checkpoint-in-glioblastoma-promising-and-challenging
#10
REVIEW
Jing Huang, Fangkun Liu, Zhixiong Liu, Hui Tang, Haishan Wu, Qianni Gong, Jindong Chen
Glioblastoma (GBM) is a severe malignant brain cancer with poor overall survival. Conventional intervention remains dismal to prevent recurrence and deterioration of GBM cell. Recent years have witnessed exciting breakthroughs in novel immune strategies, especially checkpoint inhibitors, some of which have become adjuvant setting after standard of care in melanoma. Several clinical trials of checkpoint inhibitors are ongoing in glioblastoma and other brain carcinomas. Plus, synergistic combinations of checkpoint inhibitors with conventional therapy strategies-radiotherapy, temozolomide, bevacizumab, and corticosteroids are now being exploited and applied in clinical settings...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28534153/health-related-quality-of-life-outcomes-from-cabaret-a-randomized-phase-2-trial-of-carboplatin-and-bevacizumab-in-recurrent-glioblastoma
#11
Kathryn M Field, Madeleine T King, John Simes, David Espinoza, Elizabeth H Barnes, Kate Sawkins, Mark A Rosenthal, Lawrence Cher, Elizabeth Hovey, Helen Wheeler, Anna K Nowak
In recurrent glioblastoma, health-related quality of life (HRQL) is a crucial trial endpoint. We examined HRQL outcomes as a secondary endpoint for patients in the CABARET randomized phase 2 trial. 122 patients were randomly allocated to bevacizumab monotherapy or bevacizumab plus carboplatin. We calculated change scores from baseline for each HRQL measure on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Brain Cancer Module (QLQ-BN20), together with time to deterioration in HRQL, and the proportion of participants with clinically meaningful improvements in specific disease-related symptoms...
May 22, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28527008/the-role-of-bevacizumab-in-the-treatment-of-glioblastoma
#12
REVIEW
Roberto Jose Diaz, Sheikh Ali, Mehreen Gull Qadir, Macarena I De La Fuente, Michael E Ivan, Ricardo J Komotar
Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. In order to review the therapeutic effect of bevacizumab in the primary and recurrent clinical setting we have performed a systematic analysis of data from the published literature. Weighted median progression free survival and overall survival were calculated and compared to standard therapy or other experimental therapies. A qualitative analysis of the limited studies on health related quality of life and effects on steroid requirements was also undertaken...
May 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28516072/bevacizumab-in-recurrent-glioma-patterns-of-treatment-failure-and-implications
#13
REVIEW
Yi Li, Saad Ali, Jennifer Clarke, Soonmee Cha
Glioblastoma, the most common primary malignant brain tumor in adults, is highly aggressive and associated with a poor prognosis. Bevacizumab, a monoclonal antibody against the vascular endothelial growth factor receptor, has increasingly been used in the treatment of recurrent glioblastoma. It has achieved excellent rates of radiographic response, but most patients will progress after only a few months. Upon recurrence, tumors may not enhance, secondary to vascular normalization. We describe four patterns of radiographic progression commonly associated with Bevacizumab failure: 1) Distant enhancing tumor, 2) Local tumor progression without enhancement, 3) Diffuse gliomatosis-like infiltration, and 4) Local or multifocal progression, with enhancement...
April 2017: Brain Tumor Research and Treatment
https://www.readbyqxmd.com/read/28514722/the-interventional-effect-of-new-drugs-combined-with-the-stupp-protocol-on-glioblastoma-a-network-meta-analysis
#14
Mei Li, Xiangqi Song, Jun Zhu, Aijun Fu, Jianmin Li, Tong Chen
OBJECTIVE: New therapeutic agents in combination with the standard Stupp protocol (a protocol about the temozolomide combined with radiotherapy treatment with glioblastoma was research by Stupp R in 2005) were assessed to evaluate whether they were superior to the Stupp protocol alone, to determine the optimum treatment regimen for patients with newly diagnosed glioblastoma. PATIENTS AND METHODS: We implemented a search strategy to identify studies in the following databases: PubMed, Cochrane Library, EMBASE, CNKI, CBM, Wanfang, and VIP, and assessed the quality of extracted data from the trials included...
May 11, 2017: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/28500559/nivolumab-for-patients-with-recurrent-glioblastoma-progressing-on-bevacizumab-a-retrospective-case-series
#15
Marc C Chamberlain, Bryan T Kim
A single institution retrospective evaluation of nivolumab following disease progression on bevacizumab in adults with recurrent glioblastoma (GBM) with an objective of determining progression free survival (PFS). There is no accepted therapy for recurrent GBM after failure of bevacizumab. 16 adults, ages 52-72 years (median 62), with recurrent GBM were treated. All patients had previously been treated with surgery, concurrent radiotherapy and temozolomide, and post-radiotherapy temozolomide. Bevacizumab (with or without lomustine) was administered to all patients at first recurrence...
May 12, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28499022/quantitative-imaging-biomarkers-for-risk-stratification-of-patients-with-recurrent-glioblastoma-treated-with-bevacizumab
#16
Patrick Grossmann, Vivek Narayan, Ken Chang, Rifaquat Rahman, Lauren Abrey, David A Reardon, Lawrence H Schwartz, Patrick Y Wen, Brian M Alexander, Raymond Huang, Hugo J W L Aerts
Background: Antiangiogenic therapy with bevacizumab is the most widely used treatment option for recurrent glioblastoma, but therapeutic response varies substantially and effective biomarkers for patient selection are not available. To this end, we determine whether novel quantitative radiomic strategies on the basis of magnetic-resonance-imaging (MRI) have the potential to noninvasively stratify survival and progression in this patient population. Methods: In an initial cohort of 126 patients, we identified a distinct set of features representative of the radiographic phenotype on baseline (pre-treatment) MRI...
May 11, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28485350/a-case-series-of-salvage-ccnu-in-high-grade-glioma-who-have-previously-received-temozolomide-from-a-tertiary-care-institute-in-mumbai
#17
V M Patil, R Abhinav, R Tonse, S Epari, T Gupta, R Jalali
INTRODUCTION: In our center, we routinely use CCNU (Lomustine) as salvage treatment in high-grade glioma patients who cannot afford bevacizumab. This exploratory analysis was done to report the efficacy and toxicity associated with this regimen. METHODS: Patients who were treated with salvage CCNU (postexposure to temozolomide) between January 2015 and August 2016 were included for this retrospective analysis. SPSS version 16 was used for this analysis. Time-to-event analysis was performed using the Kaplan-Meier method...
October 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28472567/long-term-benefit-of-intra-arterial-bevacizumab-for-recurrent-glioblastoma
#18
Rachel A Alter, Timothy G White, Andrew A Fanous, Shamik Chakraborty, Christopher G Filippi, David J Pisapia, Apostolos John Tsiouris, John A Boockvar
Standard treatment for recurrent GBM is not yet established. We present a case demonstrating the benefit of intra-arterial (IA) bevacizumab with blood brain barrier disruption (BBBD) for the treatment of recurrent GBM. A 31 year-old man diagnosed with GBM, following primary resection, received temozolomide. After a second resection, he received one dose of IA bevacizumab with BBBD using mannitol, preventing regrowth for 2.5 years. Following tumor regrowth, the patient received another dose of IA bevacizumab with BBBD, which has prevented regrowth for another year...
May 2017: Journal of Experimental Therapeutics & Oncology
https://www.readbyqxmd.com/read/28467795/survival-benefit-of-glioblastoma-patients-after-fda-approval-of-temozolomide-concomitant-with-radiation-and-bevacizumab-a-population-based-study
#19
Ping Zhu, Xianglin L Du, Guangrong Lu, Jay-Jiguang Zhu
Few population-based analyses have investigated survival change in glioblastoma multiforme (GBM) patients treated with concomitant radiotherapy-temozolomide (RT-TMZ) and adjuvant temozolomide (TMZ) and then bevacizumab (BEV) after Food and Drug Administration (FDA) approval, respectively. We aimed to explore the effects on survival with RT-TMZ, adjuvant TMZ and BEV in general GBM population based on the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR) databases. A total of 28933 GBM patients from SEER (N = 24578) and TCR (N = 4355) between January 2000 and December 2013 were included...
April 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/28446727/bevacizumab-combined-with-chemotherapy-for-glioblastoma-a-meta-analysis-of-randomized-controlled-trials
#20
Shou-Bo Yang, Kai-Di Gao, Tao Jiang, Shu-Jun Cheng, Wen-Bin Li
Bevacizumab, as antibodies, were applied to inhibit tumor angiogenesis by preventing activation of vascular endothelial growth factor receptor. We analyzed four clinical trials, including 607 patients, to investigate the efficacy and safety of bevacizumab when combined with chemotherapy for the treatment of glioblastomas. Results demonstrated that bevacizumab when combined with chemotherapy improved progression-free survival (HR = 0.66; 95% CI 0.56-0.78; p < 0.00001) compared with bevacizumab or chemotherapy alone...
April 7, 2017: Oncotarget
keyword
keyword
80321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"